Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Cash from Investing Activities of -$713000.0 for Q1 2026, down 24.22% on a QoQ basis from -$574000.0 in Q4 2025, and down 18.05% year-over-year from -$870004.0 in Q1 2025.
Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$713000.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 18.05% year-over-year to -$713000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 34.59% YoY) and the FY2025 annual result came in at -$2.4 million, down 90.28% from the prior year.
- Cash from Investing Activities was -$713000.0 for Q1 2026 at Bicycle Therapeutics, down from -$574000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$12000.0 in Q1 2024 and bottomed at -$9.8 million in Q2 2022.
- A 5-year average of -$1.5 million and a median of -$574000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 5630.41% — and 2024, when it jumped 99.43%.
- Bicycle Therapeutics' Cash from Investing Activities stood at -$1.4 million in 2022, then soared by 96.48% to -$51000.0 in 2023, then slumped by 621.57% to -$368000.0 in 2024, then tumbled by 55.98% to -$574000.0 in 2025, then fell by 24.22% to -$713000.0 in 2026.
- Business Quant data shows BCYC's Cash from Investing Activities at -$713000.0 in Q1 2026, -$574000.0 in Q4 2025, and -$674000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Bicycle Therapeutics | 274.55 Mn | 274.55 Mn | - | -713,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -713,000.00 |
| Mar 31, 2026 | -713,000.00 |
| Dec 31, 2025 | -574,000.00 |
| Dec 31, 2025 | -574,000.00 |
| Sep 30, 2025 | -674,000.00 |
| Sep 30, 2025 | -674,000.00 |
| Jun 30, 2025 | -498,000.00 |
| Jun 30, 2025 | -498,000.00 |
| Mar 31, 2025 | -604,000.00 |
| Mar 31, 2025 | -604,000.00 |
| Dec 31, 2024 | -368,000.00 |
| Dec 31, 2024 | -368,000.00 |
| Sep 30, 2024 | -435,000.00 |
| Sep 30, 2024 | -435,000.00 |
| Jun 30, 2024 | -420,000.00 |
| Jun 30, 2024 | -420,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | -51,000.00 |
| Dec 31, 2023 | -51,000.00 |